Ondansentron and dexamethasone treatment with different dosing schedules (24 versus 32 mg) in patients with non-small-cell lung cancer under cisplatin-based chemotherapy: A randomized study

Chemotherapy

Volumn 46, Issue 5, 2000, Pages 364-370

  Tsavaris, N ^a   Kosmas, Ch ^a   Vadiaka, M ^a   Kanelopoulos, P ^a   Kontos, A ^a   Katsorida, M ^a   Agelopoulou, A ^a   Vrizidis, N ^a   Fotia, M ^a   Papoutsis, K ^a   Koufos, Ch ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cisplatin chemotherapy; Dexamethasone; Emesis; Non small cell lung cancer; Ondansentron

Indexed keywords

CISPLATIN; DEXAMETHASONE; ETOPOSIDE; MITOMYCIN C; ONDANSETRON; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHORESIS; DIARRHEA; DISEASE CLASSIFICATION; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; HEADACHE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; VOMITING; XEROSTOMIA;

EID: 0033803084     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007310     Document Type: Article

References (27)

1. Einhorn LH, Nagy C, Werner K, Finn AL: Ondansentron: A new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 1990;8:731-735.
2. Blackwell C, Harding SM: The clinical pharmacology of ondansentron. Eur J Cancer Clin Oncol 1989;25: 21-24.
3. Aapro MS: Serotonin antagonists. Rev Cancer 1989;3:134-138.
4. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL: Efficacy of ondansentron (GR 38032F) and the role of serotonin in cisplatin induced nausea and vomiting. N Engl J Med 1990;12:810-815.
5. Lip H: Ondansentron, a new antiemetic therapy for oncology. An overview: Scand J Gastrenterol 1990;178:55-61.
6. Milne RJ, Heel RC: Ondansentron. Therapeutic case as an antiemetic. Drugs 1991;41:574-595.
7. Smith RN: Safety of ondansentron. Eur J Cancer Clin Oncol 1989;25: 547-550.
8. Marty M: Ondansentron in the prophylaxis of acute cisplatin-induced nausea and vomiting. Eur J Cancer Clin Oncol 1989;25:541-545.
9. Harvey VJ, Evans BD, Michael PL, Mak D, Neave LM, Langley GB, Dickson DS: Reduction of carboplatin-induced emesis by ondansentron. Br J Cancer 1991;63:942-944.
10. Tsavaris N, Charalambidis G, Pagou M, Karabelis A, Mylonakis N, Bacoyiannis Ch, Kosmidis P: Comparison of ondansentron (GR 38032F) vs ondansentron plus alprazolam as antiemetic prophylaxis during cisplatin containing chemotherapy. Am J Clin Oncol 1994;17: 516-521.
11. Tsavaris N, Mylonakis N, Bacoyiannis Ch, Katsikas M, Lioni A, Kosmidis P: Comparison of ondansentron (GR 38032F) vs ondansentron plus methylprednisolone as antiemetic prophylaxis during cisplatin containing chemotherapy. J Pain Symptom Manage 1994;9:254-258.
12. Grunberg SM: Making chemotherapy easier. N Engl J Med 1990;322: 846-848.
13. Whitehead VM: Cancer treatment needs better antiemetics. N Engl J Med 1975;293:199-200.
14. Seigel LJ, Longo DL: The control of chemotherapy-induced emesis. Ann Intern Med 1981;95:352-359.
15. Morrow GR: The assessment of nausea and vomiting: Past problems current issues, and suggestions for future research. Cancer 1984;53: 2267-2278.
16. De Mulder PH, Seynaeve C, Vermorken JB, Van Liessum PA, Nolsjevdevic S, Allman EL, Beranek P, Verweij J: Ondansentron compared with high dose metoclopramide in prophylaxis of acute and delayed cisplatin induced nausea and vomiting. Ann Intern Med 1990;113:834-840.
17. Kaasa S. Kvaloy S, Dicato MA, Ries F, Huys JV, Rover E, Carruthers L: A comparison of ondansentron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer Clin Oncol 1990;26:311-314.
18. Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pajada-Lauraine E, Paule B, Paes D, Bons J: Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist (Ondansentron) (GR 38032F) with high dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:816-821.
19. Priestman TJ, Roberts JT, Lucraft H, Collis CH, Adams M, Upadhyaya BK, Priestman S: Results of a randomized double blind comparative study of ondansentron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol 1990;2:71-75.
20. Hainsworth J, Harvey W, Pendergrass K, Kasimis B, Oblon D, Monaghan G, Gandara D, Hesketh P, Khojasyeh A, Harker G et al: A single-blind comparison of intravenous ondansentron, a selective serotonine antogonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high dose cisplatin chemotherapy. J Clin Oncol 1991;9:721-728.
21. Hainsworth JD, Omura GA, Khojasteh A, Bryson JC, Finn AL: Ondansentron (GR 38032F): A novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy. Am J Clin Oncol 1991;14:336-340.
22. Tsavaris N, Charalambidis G, Ganas N, Pagou M, Karabelis A, Benou N, Tsikalakis D, Kosmidis P: The influence of ondansentron and Metoclopramide on electrolyte inbalance in patients with nausea and vomiting receiving cisplatin based chemotherapy. Acta Oncol, accepted.
23. Zofran (Ondancentron) Satellite Symposium Abstracts, Copenhagen Falkoner Center, Copenhagen, 1990.
24. Zofran (Ondancentron) Satellite Symposium Abstracts, Hamburg Congress Center, Hamburg 17 Aug 1990.
25. Gralla R: Approaches to management of emesis. Clinician 1988;6: 26-39.
26. Tsavaris N, Fountzilas G, Mylonakis N, Athanassiadis A, Kosmas C, Karakousis C, Bacoyiannis C, Kosmidis P: A randomized comparative study of antiemetic prophylaxis with ondansentron in a single 32-mg loading dose versus 8 mg every 6 h in patients undergoing cisplatin-based chemotherapy. Oncology 1998;55:513-516.
27. Tsavaris NB, Tsaroucha-Noutsou E, Karvounis N, Bacoyannis C, Pagou M, Kosmidis P: Comparison of different schedules of ondansentron (GR 38032F) administration during cisplatin-based chemotherapy: a randomized trial. Chemotherapy 1995;41:70-76.